tiprankstipranks
Aptevo Therapeutics Inc (APVO)
NASDAQ:APVO

Aptevo Therapeutics Stock Analysis & Ratings

APVO Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$3.03 - $22.68
Previous Close$3.58
Volume29.22K
Average Volume (3M)176.78K
Market CapN/A
Enterprise ValueN/A
P/E Ratio-0.6
Beta5.37
Next EarningsAug 11, 2022
Next Dividend Ex-DateN/A
Dividend YieldN/A
Smart ScoreN/A


Financials

Yearly

P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

---

Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.

---

APVO FAQ

What was Aptevo Therapeutics’s price range in the past 12 months?
Aptevo Therapeutics lowest stock price was $3.03 and its highest was $22.68 in the past 12 months.
    What is Aptevo Therapeutics’s market cap?
    Currently, no data Available
    What is Aptevo Therapeutics’s price target?
    The average price target for Aptevo Therapeutics is $20.00. This is based on 1 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
    The highest analyst price target is $20.00 ,the lowest forecast is $20.00. The average price target represents 458.66% Increase from the current price of $3.58.
      What do analysts say about Aptevo Therapeutics?
      Aptevo Therapeutics’s analyst rating consensus is a ‘Moderate Buy. This is based on the ratings of 1 Wall Streets Analysts.
        When is Aptevo Therapeutics’s upcoming earnings report date?
        Aptevo Therapeutics’s upcoming earnings report date is Aug 11, 2022 which is in 38 days.
          How were Aptevo Therapeutics’s earnings last quarter?
          Aptevo Therapeutics released its earnings results on May 12, 2022. The company reported -$1.59 earnings per share for the quarter, missing the consensus estimate of -$1.15 by -$0.44.
            Is Aptevo Therapeutics overvalued?
            According to Wall Street analysts Aptevo Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
              Does Aptevo Therapeutics pay dividends?
              Aptevo Therapeutics does not currently pay dividends.
              What is Aptevo Therapeutics’s EPS estimate?
              Aptevo Therapeutics’s EPS estimate is -$1.33.
                How many shares outstanding does Aptevo Therapeutics have?
                Aptevo Therapeutics has 5,007,242 shares outstanding.
                  What happened to Aptevo Therapeutics’s price movement after its last earnings report?
                  Aptevo Therapeutics reported an EPS of -$1.59 in its last earnings report, missing expectations of -$1.15. Following the earnings report the stock price went up 11.257%.
                    Which hedge fund is a major shareholder of Aptevo Therapeutics?
                    Currently, no hedge funds are holding shares in APVO

                    ---

                    Aptevo Therapeutics Stock Analysis

                    Smart Score
                    N/A
                    Not Ranked
                    1
                    2
                    3
                    4
                    5
                    6
                    7
                    8
                    9
                    10
                    Price Target
                    $20.00
                    ▲(458.66% Upside)
                    Moderate Buy
                    This stock does not have enough of the key information we need to rate it accurately. Smart Score is calculated for stocks traded in Nasdaq, NYSE, TSE and LSE with a market cap above $30M and average 3 months trading volume above $30K.
                    Learn more about TipRanks Smart Score

                    Company Description

                    Aptevo Therapeutics Inc

                    Aptevo Therapeutics, Inc. is a biotechnology company, which engages in the discovery, development, commercialization and sale of novel oncology and hematology therapeutics to improve patients lives. Its pipeline includes APVO210, APVO436, ROR1 Candidate, and ALG.APV-527. The company was founded on February 22, 2016 and is headquartered in Seattle, WA.

                    ---
                    Similar Stocks
                    Company
                    Price & Change
                    Follow
                    Pfizer
                    Gilead Sciences
                    Amgen
                    AbbVie
                    Johnson & Johnson

                    Popular Stocks

                    ---
                    What's Included in PREMIUM?
                    Make informed decisions based on Top Analysts' activity
                    Know what industry insiders are buying
                    Get actionable alerts from top Wall Street Analysts
                    Find out before anyone else which stock is going to shoot up
                    Get powerful stock screeners & detailed portfolio analysis